MEDraysintell
Projects Increasing Mergers and Acquisitions in Nuclear Medicine
New market report notes that
approximately $10 billion in M&A transactions have occurred over the past
four years, with signs indicating continuing future growth.
With
the recent announcement by Novartis to acquire Endocyte, interest from the
conventional pharmaceutical industry towards radiopharmaceuticals and in particular
radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few
years ago by MEDraysintell. Numerous major acquisitions have involved the
conventional pharmaceutical industry over the past four years.
MEDraysintell
noted that other mergers within the radiopharmaceutical industry showed
consolidation of this industry. The company said there are great chances that
additional mergers and acquisitions (M&A) will take place within the next
12 months. At the same time, the conventional pharmaceutical industry is now
looking for new opportunities in early-stage research programs in this area.
MEDraysintell anticipates that the global market will reach $5.9 billion in
2019, and it is now expected that radiotherapeutics will represent more than 60
percent of the $26 billion nuclear medicine market by 2030.
To read more please visit:
https://www.itnonline.com/content/medraysintell-projects-increasing-mergers-and-acquisitions-nuclear-medicine
Source:
ITN online